|Bid||104.65 x 1400|
|Ask||104.72 x 800|
|Day's Range||104.19 - 107.30|
|52 Week Range||71.85 - 119.65|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||475.77|
|Earnings Date||Feb 02, 2020 - Feb 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 27, 1995|
|1y Target Est||121.28|
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and clinical development milestones for 2020. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 13 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time).
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019 granting Neurocrine Biosciences an option to license ACT-709478, a potent, selective, orally-active, and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The option also includes a research collaboration to discover, identify and develop additional novel T-type calcium channel blockers.
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) on Monday, Jan. 13, 2020, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
One thing nearly everyone can agree on about the past decade is that it has been very, very good for stock market investors. The Russell 1000 large-company index, which tracks the 1,000 biggest U.S. stocks by market value, has gained roughly 252% since the start of the 2010s, including reinvested dividends.Some stocks have done far better. Microsoft (MSFT) awoke from its long slumber and jumped 545% over the past decade. Dollar General (DG) made a lot of bucks, gaining 632%. And Ulta Beauty (ULTA) has made a lovely 1,325% gain.But those aren't the tippy-top stocks of the Russell 1000. Not even close.Here are the top 10 large-company stocks of the decade, as well as a look at what put them on top of the heap. We chose the Russell 1000 because it offers an even broader look at the stock market than the S&P; 500, but still excludes smaller companies where extremely outsize gains are more common and can more easily come from a single, quick driver. SEE ALSO: The 20 Best Stocks to Buy for 2020
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, announced today that it will provide updates on its partnered epilepsy programs at the American Epilepsy Society (AES) Annual Meeting held in Baltimore, MD.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...
SAN DIEGO and BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NBIX) and Xenon Pharmaceuticals Inc. (XENE) announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. Neurocrine Biosciences gains an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]
SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that the Journal of Clinical Psychopharmacology1 published long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine) capsules, demonstrating that treatment with once-daily 40 mg or 80 mg of INGREZZA reduced involuntary movements in adults who had moderate or severe tardive dyskinesia (TD) and clinical diagnoses of schizophrenia, schizoaffective disorder or a mood disorder.
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy ...